Sigrid Therapeutics' silica-based biomaterial SiPore15 [® ] granted US patent for treatment and prevention of obesity and overweight

Stockholm, Sweden, July 1, 2020. Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO). The patent covers the use of Sigrid's medical device product SiPore15 ^® for the reduction of body fat and the prevention and treatment of obesity and overweight. SiPore15 ^® is based on the company's research breakthrough around specially engineered mesoporous silica particles (MSP). The US patent (No. 10,695,294) grants exclusive sales rights for the company's lead product until 2033 in the US.

The US patent complements previously granted patents in other key commercial markets, including Japan, Australia, Canada and Israel, among others, covering the SiPore ^® platform technology and the company's lead product SiPore15 ^® for use as a medical preparation and as a dietary supplement for the prevention and treatment of metabolic diseases. Sigrid plans to file further patent applications in other strategically important markets and more granted patents are expected shortly.

Sana Alajmovic, Co-Founder and CEO, Sigrid Therapeutics, comments:

" The new patent further strengthens Sigrid's global IP portfolio and at the same time increases the commercial attractiveness of our product to include the prevention and treatment of obesity and overweight in the world's most important global market. The patent is a recognition of the level of innovation and the newness behind our product . It also validates our expertise in developing innovative and patentable silica-based biomaterials for the prevention and treatment of diabetes and its related diseases," concludes Sana Alajmovic.